Ajanta Pharma Share Price

Ajanta Pharma

CMP as on 12-May-21 16:00

₹ 2,005.00
62.05 3.19%


₹ 1,962.00

Turnover (lac)

₹ 3,788

Prev. Close

₹ 1,942.95

Day's Vol (shares)

₹ 1,88,951

Day's Range (₹)

₹ 1,890.00
₹ 2,009.90

CMP as on12-May-21 15:54

₹ 2,010.70
68.2 3.51%


₹ 1,942.50

Turnover (lac)

₹ 137

Prev. Close

₹ 1,942.50

Day's Vol (shares)

₹ 6,076

Day's Range

₹ 1,930.00
₹ 2,010.70

Ajanta Pharma is a specialty pharmaceutical company engaged in development, manufacture and marketing of quality finished dosages in domestic and international markets. The company produces a comprehensive range of specialty products targeting different therapeutic segments. The companys business includes Branded Generics in emerging markets of Asia and Africa, Generics in the developed markets of USA and Institution sales. The branded generics business is spread in India and more than 30 emerging countries across Africa, CIS, the Middle East and South East Asia. In India, Ajanta Pharma has presence in high growth specialty segments of cardiology, dermatology, ophthalmology and pain management.In branded generic business in emerging markets in Asia and Africa, Ajanta Pharmas products cater to therapeutic segments like Anti-Biotic, Anti-Malarial, Anti-Diabetic, Cardiology, Gynecology, Orthopedics, Pediatric, Respiratory & General Health products. The companys institutional business comprises of supplies to various government bodies in India and supply of Anti-Malarial products under WHO approved programs in Africa.Ajanta Pharma operates 7 state-of-the-art manufacturing facilities in India and Mauritius. 2 of the facilities in India have been successfully approved by US FDA. The company has an advanced Research & Development Centre in Mumbai for finished formulations and Active Pharmaceutical Ingredient (API) synthesis of different dosage forms. Established in 1973 and headquartered in Mumbai-India, the company has a mission of Serving Global Health Care Needs Worldwide. Ajanta has been consistently providing affordable and quality medicines to patients in different parts of the world. The company began its operation in the year 1973 by setting up a small repackaging unit. The company also launched 4 products under its own brand name for repackaged pharma items in the same year. In 1979, the Company set up its 1stManufacturing factory in Chikalthana, Maharashtra and also launched 1st own manufactured OTC product- Pinkoo Gripe Water, making a mark in the industry by deviating from easy path of following leaders in gripe water industry. A New Manufacturing Facility was built by the company in the year 1984 in Paithan and the company also entered in institutional business. During the period from 1995 to 1998, the company established dedicated R&D facility at Kandivli and also set up manufacturing facilities in Mauritius and CIS. In 2000, the company went public with shares by listing shares in BSE and NSE and also undertook major expansion of manufacturing facilities. In 2002, the company entered domestic prescription market with speciality segment force. In 2007, the company expanded its R&D facility with independent premises in Kandivali. The company also got USFDA Approval for its Paithan manufacturing facility in 2008. In 2009, the company started Active Pharmaceutical Ingredient (API) plant in Waluj, Aurangabad for captive use. During the year, the company bought a manufacturing facility at Chitegaon in Aurangabad, Maharashtra to fuel the companys growth. Also during the year, Ajanta Pharma became the first generic company in the world to get WHO Geneva Pre-qualification for Anti-Malarial Drug.In 2010, Ajanta Pharma entered Philippines market with unique product portfolio through Ajanta Pharma Philippines Inc. In 2011, Ajanta Pharma emerged as a strong speciality player in domestic market in Ophthalmology, Dermatology and Cardiology with many brands holding leadership positions.In 2012, Ajanta Pharma was ranked among the Top 10 pharma companies in Franco Africa. During the year 2013, Ajanta Pharma commenced sales to the US market. In 2014, the company set up its 2nd dedicated R&D centre at Kandivli in Mumbai for India and emerging markets. During the year, the company inaugurated a new facility in Dahej, Bharuch, Gujarat for catering to the requirements of markets like USA, WHO and emerging markets. In 2015, the company announced the launch of Montelukast Sodium Oral Granules. The company also announced the launch of Montelukast IR Tablets and Montelukast Chewable Tablets in US market.In 2017, the company inaugurated and commissioned 1st phase at a new facility in Guwahati, Assam. The companys Dahej, Gujarat facility was approved by the USFDA without any observation in April 2017.On 11 July 2017, Mr. Yogesh M. Agrawal, Managing Director of Ajanta Pharma (APL) informed the company that promoters have sold 27 lakh equity shares in APL, representing about 3.07% of APLs equity shares. Consequent to sale, promoter holding has come down from 73.78% to 70.71% in APL. This sale has been done to provide liquidity to the promoters and the proceeds will be utilized for personal use.On 9 February 2018, Ajanta Pharma announced that its formulation facility at Dahej in Gujarat was inspected by USFDA from 5 to 9 February 2018. At the end of the inspection, no Form 483 was issued to the company by the USFDA.

  • Chairman

    Mannalal B Agrawal
  • Vice Chairman

    Madhusudan B Agrawal
  • Managing Director

    Yogesh Agrawal
  • Independent Director

    Chandrakanth M Khetan
  • Company Secretary

    Gaurang Shah
  • Joint Managing Director

    Rajesh M Agrawal
  • Independent Director

    K H Viswanathan
  • Independent Director

    Prabhakar Dalal
  • Independent Director

    Anjana Grewal

Registered Office

Ajanta House,
Charkop Kandivli (W),Mumbai,


C-101 247 Park,
Vikhroli West,Mumbai-400083